Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent Inc (NYSE: CTLT) delivers essential pharmaceutical development solutions and manufacturing services for global healthcare partners. This dedicated news hub provides investors and industry professionals with timely updates on Catalent's operational milestones, strategic initiatives, and regulatory developments.
Access authoritative reporting on material events including clinical manufacturing advancements, drug delivery innovations, and global supply chain expansions. Our curated collection features earnings disclosures, partnership announcements, and facility updates directly impacting Catalent's market position.
Key focus areas include bioavailability enhancement technologies, commercial packaging solutions, and biologics manufacturing capabilities. Monitor critical updates through verified press releases and objective analysis of Catalent's role in accelerating therapeutic development timelines.
Bookmark this page for streamlined tracking of CTLT's progress in formulation science, regulatory submissions, and capacity investments across its global manufacturing network.
Highlander Partners announced that Catalent will acquire its portfolio company, Bettera Holdings, for $1 billion. Bettera, headquartered in Plano, Texas, is a top manufacturer of gummy vitamins and supplements, operating four facilities in California, Virginia, New Jersey, and Indiana. Highlander formed Bettera through four acquisitions since 2017. The acquisition aims to enhance Catalent's consumer health business, leveraging the growing demand for gummy and lozenge formats. The deal is expected to close by the end of 2021, subject to customary conditions.
Catalent Inc. (NYSE: CTLT) announced its acquisition of Bettera Holdings, LLC for $1 billion. This strategic move will enhance Catalent's offerings in the nutritional supplements market, particularly in gummy, soft chew, and lozenge segments. The acquisition is expected to close by year-end 2021 and includes Bettera’s production facilities across the U.S. The merger aims to leverage both companies' capabilities to provide advanced solutions in consumer health and beauty, unlocking significant synergies. Catalent plans to fund the acquisition through cash and existing credit facilities.
Catalent, Inc. (NYSE: CTLT) reported Q4'21 net revenue of $1.19 billion, a 25% increase from Q4'20, driven by a 26% organic revenue growth. Fiscal 2021 net revenue reached $4.00 billion, up 29% year-over-year. Q4'21 net earnings were $182 million, with an adjusted EBITDA of $348 million. The company announced a proposed $1 billion acquisition of Bettera, enhancing its position in nutritional supplements. For FY'22, it projects net revenue growth of 8-13% and Adjusted EBITDA growth of 11-18%.
Catalent, Inc. (NYSE: CTLT) will release its fourth-quarter financial results for fiscal year 2021, which ended June 30, 2021, on August 30, 2021, before market open. A management webcast will follow at 8:15 a.m. ET to discuss these results. Investors can access the webcast through Catalent’s website. A supplemental slide presentation will also be available for review prior to the webcast and will be accessible for 90 days post-event.
Catalent, Inc. (NYSE: CTLT) announced that as of July 1, 2021, 97% of its electricity usage is sourced from renewable energy, including wind, solar, hydroelectric, and biomass. This move is part of Catalent's commitment to sustainability, aligning with their agreement with the Science-Based Target initiative (SBTi) to set greenhouse gas emission reduction goals. The CEO, John Chiminski, emphasized the importance of this progress for the biopharma sector's long-term sustainability and environmental strategy.
Catalent, Inc. (NYSE: CTLT) announced that its Chair and CEO, John Chiminski, will present virtually at the Biopharma CEO Investor Forum on June 8, 2021, at 9:45 a.m. ET. The presentation will be available via a live webcast and can be replayed afterward. Catalent is a prominent global provider focused on advanced delivery technologies and manufacturing solutions across various sectors, including drugs and biologics. With over 85 years of experience and more than $3 billion in revenue for fiscal year 2020, Catalent employs over 15,000 staff worldwide.
Catalent, Inc. (NYSE: CTLT), a leading provider of advanced delivery technologies, announced that its executive leadership team will present virtually at two upcoming conferences. The presentations are scheduled for June 1, 2021, at the Jefferies Healthcare Conference at 10:30 a.m. ET, and June 3, 2021, at the William Blair 41st Annual Growth Stock Conference at 11:40 a.m. ET. A live webcast of the events will be available at investor.catalent.com and can be replayed afterwards.
Catalent, Inc. (NYSE: CTLT), a global leader in advanced delivery technologies and manufacturing solutions, will present virtually at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 11:00 a.m. ET. The presentation will be available for live streaming and replay on their investor website. With over 85 years of experience, Catalent specializes in bringing drugs, biologics, and consumer health products to market efficiently, generating over $3 billion in revenue in FY 2020, and employing over 14,000 staff across 40 facilities worldwide.
Catalent, Inc. (NYSE: CTLT) has released its Corporate Responsibility (CR) Report for fiscal year 2020, highlighting its commitment to sustainability amidst the COVID-19 pandemic. The report outlines progress in energy efficiency, diversity, and community investments, with a goal for all sites to achieve wastewater discharge standards by fiscal 2024. Key achievements include the completion of 50 energy efficiency projects and six sites transitioning to renewable electricity. The company also addressed workforce well-being and expanded its community initiatives, benefiting 500 non-profits during the fiscal year.
Catalent, Inc. (NYSE: CTLT) has appointed Thomas Castellano as Senior Vice President and Chief Financial Officer, effective June 1, 2021. He succeeds Wetteny Joseph, who is leaving to join Zoetis Inc. Castellano, a long-term employee with over 13 years at Catalent, has held several senior financial roles, most recently as Global Vice President of Operational Finance. The Board expressed gratitude to Joseph for his service and praised Castellano's contributions, highlighting the company’s effective succession planning and strong leadership development.
